A new study published in the journal of Public Library of Science found that the triglyceride levels of individuals with ...

This study highlights the efficacy of home-based tDCS in treating major depressive disorder, with significant improvements in ...

Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the ...

The app, called Rejoyn, is cleared as a supplement to currently approved therapies and works by using specifically designed ...

In a recent study published in Nature, researchers used advanced brain imaging techniques to explore how certain brain networks differ in people with depression. They discovered that a specific brain ...

Mirtazapine is an FDA- approved, prescription-only medication for major depressive disorder in adults. The medication works by increasing certain hormones in the brain to improve mood. Whichever ...

A new Macquarie University study suggests that instead of relying on the 'bible' of mental health diagnosis, we need a ...

New research underscores the role of the immune system in depression, linking inflammation to poor response to standard antidepressants and highlighting the importance of personalized medicine in ...

About the SPN-820 Phase 2a Clinical Study The study is a Phase 2a open-label study in 40 subjects with major depressive disorder (MDD). The primary objective of the study is to assess efficacy in MDD, ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that ...

Cybin secures a U.S. patent for its CYB005 program targeting CNS disorders and prepares to launch a Phase 3 trial for CYB003 in major depressive disorder.

Supernus Pharmaceuticals Inc. (SUPN) announced a promising data from its exploratory open-label Phase 2a clinical study of SPN-820 in ...